DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B. et al.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
J Clin Oncol 2013;
31: 88-94
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.